NO970165L - Corticotropin release factor-binding protein inhibitors and their use - Google Patents

Corticotropin release factor-binding protein inhibitors and their use

Info

Publication number
NO970165L
NO970165L NO970165A NO970165A NO970165L NO 970165 L NO970165 L NO 970165L NO 970165 A NO970165 A NO 970165A NO 970165 A NO970165 A NO 970165A NO 970165 L NO970165 L NO 970165L
Authority
NO
Norway
Prior art keywords
crf
binding protein
ligand inhibitor
brain
protein inhibitors
Prior art date
Application number
NO970165A
Other languages
Norwegian (no)
Other versions
NO970165D0 (en
Inventor
Dominic P Behan
Phillip J Lowry
Jr Wylie Walker Vale
Stephen C Heinrichs
Steven W Sutton
Jean E F Rivier
Errol Desouza
Original Assignee
Neurocrine Biosciences Inc
Salk Inst
Univ Reading
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/008867 external-priority patent/WO1996002569A1/en
Application filed by Neurocrine Biosciences Inc, Salk Inst, Univ Reading filed Critical Neurocrine Biosciences Inc
Publication of NO970165D0 publication Critical patent/NO970165D0/en
Publication of NO970165L publication Critical patent/NO970165L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nivåer av fri kortikotropin-frigjørende faktor (CRF) i hjernen økes ved at pasienten administreres en ligand-inhibitor av et CRF/GRF-bindende protein- kompleks. Ligand-inhibitoren binder seg til CRF-bindende protein og forårsaker frigjøring av CRF. Ligand-inhibitoren kan være et peptid som skriver seg fra CRF eller et beslektet protein eller et ikke-peptid. Administrering av ligand-inhibitoren kan bevirke forbedring av læring og hukommelse, resultere i nedsatt næringsinntak eller bevirke behandling av sykdommer assosiert med lave nivåer av CRF i hjernen, særlig Alzheimers sykdom. Det tilveiebringes også en fremgangsmåte for screening av forbindelser for seleksjon av særiig effektive CRF-antagonister for in vivo administrering til pattedyr.Levels of free corticotropin-releasing factor (CRF) in the brain are increased by administering to the patient a ligand inhibitor of a CRF / GRF-binding protein complex. The ligand inhibitor binds to CRF-binding protein and causes the release of CRF. The ligand inhibitor may be a peptide derived from CRF or a related protein or a non-peptide. Administration of the ligand inhibitor may improve learning and memory, result in decreased nutritional intake or cause treatment of diseases associated with low levels of CRF in the brain, especially Alzheimer's disease. There is also provided a method for screening compounds for selection of highly effective CRF antagonists for in vivo administration to mammals.

NO970165A 1994-07-15 1997-01-14 Corticotropin release factor-binding protein inhibitors and their use NO970165L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27624094A 1994-07-15 1994-07-15
US48477695A 1995-06-07 1995-06-07
PCT/US1995/008867 WO1996002569A1 (en) 1994-07-15 1995-07-14 Corticotropin-releasing factor-binding-protein inhibitors and their use

Publications (2)

Publication Number Publication Date
NO970165D0 NO970165D0 (en) 1997-01-14
NO970165L true NO970165L (en) 1997-03-14

Family

ID=26957870

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970165A NO970165L (en) 1994-07-15 1997-01-14 Corticotropin release factor-binding protein inhibitors and their use

Country Status (7)

Country Link
EP (1) EP0771323A1 (en)
JP (2) JPH10503187A (en)
CN (1) CN1157620A (en)
AU (1) AU705984B2 (en)
CA (1) CA2195197A1 (en)
MX (1) MX9700413A (en)
NO (1) NO970165L (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043752A (en) * 2016-12-07 2017-08-15 陈锋 Hybridoma cell strain and the anti-CRH antibody N D19 based on hybridoma cell strain and its application of context of detection
CN107058237A (en) * 2016-12-07 2017-08-18 陈锋 Hybridoma cell strain and the anti-CRH antibody C D17 based on hybridoma cell strain and its application of context of detection
IL300478A (en) * 2020-08-12 2023-04-01 Spruce Biosciences Inc Methods and compositions for treating polycystic ovary syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein

Also Published As

Publication number Publication date
NO970165D0 (en) 1997-01-14
EP0771323A1 (en) 1997-05-07
JP2001348400A (en) 2001-12-18
CN1157620A (en) 1997-08-20
AU3128395A (en) 1996-02-16
AU705984B2 (en) 1999-06-03
JPH10503187A (en) 1998-03-24
CA2195197A1 (en) 1996-02-01
MX9700413A (en) 1998-05-31

Similar Documents

Publication Publication Date Title
ES2170104T3 (en) INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS.
ATE171192T1 (en) PEPTIDES AND PROTEINS, METHOD FOR THE PRODUCTION THEREOF AND THE USE AS CHOLESTEROL ACCEPTORS
ATE140388T1 (en) COMPOSITIONS CONTAINING OMEGA CONOTOXIN PEPTIDE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF ISCHEMIA-TYPE NEURONAL INJURY
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
MY102806A (en) Human interleukin-3 and muteins thereof
ATE255126T1 (en) SUPPRESSION OF IMMUNE RESPONSE BY INHIBITING CATHEPSIN S
GB9519275D0 (en) Substances and their therapeutic use
ATE313802T1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
ATE294236T1 (en) PROMOTER OF THE TIE RECEPTOR PROTEIN KINASE
DE69935078D1 (en) A MUTANT PHOSPHOLAMBAN MOLECULES AND THEIR USE FOR THE TREATMENT OF HEART DISEASES AND HEART FAILURES
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS
NO970165L (en) Corticotropin release factor-binding protein inhibitors and their use
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
DE69607034D1 (en) PCNA BINDING SUBSTANCE
DE69428272D1 (en) LO-CD2A ANTIBODIES AND THEIR USE FOR INHIBITING T CELL ACTIVATION AND GROWTH
Karelin et al. Fragments of functional proteins: role in endocrine regulation
NO961423D0 (en) Oligopeptides derived from C-reactive protein fragments
DE69834929D1 (en) USE OF AN ORGANIC NUTRITIONAL AGENT
DE69712182D1 (en) PEPTIDES AND THEIR USE IN THE THERAPY OF DISEASES OF THE CELEBIA FORM
ES2063161T3 (en) MODIFIED PROTEINS.
ATE239492T1 (en) USE OF A BPI PROTEIN TO PRODUCE A MEDICATION FOR THE TREATMENT OF CHRONIC HEART DISEASE
ATE452139T1 (en) PEPTIDE BAIT FOR THE PRODUCTION OF MEDICATIONS USED FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES OR PROBLEMS ASSOCIATED WITH THE APPEARANCE OF ANTIBODIES DIRECTED TO EXOGENE PROTEINS
DE60034874D1 (en) INTERNAL RIBOSOM SUBMISSION (IRES), VECTOR OF THESE CONTAINED AND ITS THERAPEUTIC USE
Rath Solution to the puzzle of human evolution
Satoh et al. Autocrine Loop between Transforming Growth Factor-ß1 and Interleukin-1ß through Smad3-and ERK-dependent Pathways in Rat Pancreatic Stellate Cells.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application